Aneurismal subarachnoid hemorrhage during the COVID-19 outbreak in a Hub and Spoke system: observational multicenter cohort study in Lombardy, Italy - Scorecard - MDSpire

Aneurismal subarachnoid hemorrhage during the COVID-19 outbreak in a Hub and Spoke system: observational multicenter cohort study in Lombardy, Italy

  • By

  • Alessandro Fiorindi

  • Marika Vezzoli

  • Francesco Doglietto

  • Luca Zanin

  • Giorgio Saraceno

  • Edoardo Agosti

  • Antonio Barbieri

  • Silvio Bellocchi

  • Claudio Bernucci

  • Daniele Bongetta

  • Andrea Cardia

  • Emanuele Costi

  • Marcello Egidi

  • Antonio Fioravanti

  • Roberto Gasparotti

  • Carlo Giussani

  • Gianluca Grimod

  • Nicola Latronico

  • Davide Locatelli

  • Dikran Mardighian

  • Giovanni Nodari

  • Jacopo Carlo Poli

  • Frank Rasulo

  • Elena Roca

  • Giovanni Marco Sicuri

  • Giannantonio Spena

  • Roberto Stefini

  • Oscar Vivaldi

  • Cesare Zoia

  • Stefano Calza

  • Marco Maria Fontanella

  • Marco Cenzato

  • October 25, 2021

  • 0 min

Share

Clinical Scorecard: Subarachnoid Hemorrhage from Aneurysms Amid the COVID-19 Pandemic: A Multicenter Observational Study in Lombardy's Hub and Spoke Healthcare System

At a Glance

CategoryDetail
ConditionAneurysmal subarachnoid hemorrhage (aSAH)
Key MechanismsRupture of cerebral aneurysm causing hemorrhage; time-dependent neurosurgical emergency
Target PopulationAdults aged 18 years or older diagnosed with aSAH in Lombardy region
Care SettingNeurosurgical Hub hospitals within a regional Hub and Spoke emergency network during COVID-19 pandemic

Key Highlights

  • COVID-19 pandemic led to reorganization of neurosurgical care into Hub and Spoke system centralizing aSAH treatment.
  • Diagnostic delay for aSAH increased significantly (+68%) during COVID-19 lockdown compared to pre-pandemic period.
  • No significant differences in severity (WFNS, Fisher grades) or gender distribution between COVID-19 and pre-pandemic groups.

Guideline-Based Recommendations

Diagnosis

  • Urgent CT scan for suspected aSAH to confirm diagnosis.
  • Screen all patients for SARS-CoV-2 infection using RT-PCR and chest imaging during pandemic.
  • Use transcranial Doppler (TCD) to diagnose vasospasm (MFV ≥120 cm/s and Lindegaard ratio ≥3).

Management

  • Centralize aSAH treatment in designated Hub hospitals during pandemic to optimize resource allocation.
  • Prioritize emergency hospitalization and treatment of aSAH patients; immediate referral from Spoke to Hub hospitals.
  • Consider shift towards endovascular treatment due to increased surgical risk in COVID-19 patients.

Monitoring & Follow-up

  • Monitor for SAH-related complications including vasospasm and ischemia via imaging and TCD.
  • Track delays in diagnosis and treatment times to improve outcomes.
  • Assess Glasgow Outcome Scale (GOS) at discharge to evaluate patient recovery.

Risks

  • Increased diagnostic delay during pandemic may worsen outcomes.
  • Potential increased surgical risk in COVID-19 positive patients necessitating treatment adjustments.
  • Conversion of neurosurgery units to COVID wards may limit access to timely neurosurgical care.

Patient & Prescribing Data

72 patients during COVID-19 lockdown and 179 patients from pre-pandemic years in Lombardy region

Treatment modalities and timing were analyzed; slight increase in diagnostic delay during COVID-19; low SARS-CoV-2 positivity (5.5%) among aSAH patients.

Clinical Best Practices

  • Implement regional Hub and Spoke systems to centralize emergency neurosurgical care during pandemics.
  • Ensure rapid diagnostic imaging and minimize delays from symptom onset to diagnosis.
  • Screen all aSAH patients for COVID-19 to guide treatment planning and infection control.
  • Use standardized scales (WFNS, Fisher, GOS) for consistent assessment and outcome tracking.
  • Maintain multidisciplinary coordination to manage SAH-related and COVID-related complications.

References

Original Source(s)

Related Content